Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas

Oncology (Switzerland)

Volumn 89, Issue 5, 2015, Pages 294-303

  Kubisch, Ilja ^a   De Albuquerque, Andreia ^b   Schuppan, Detlef ^c,d,f   Kaul, Sepp ^b   Schaich, Markus ^e   Stölzel, Ulrich ^a  

^a KLINIKUM CHEMNITZ   (Germany)

^b Zentrum fur Diagnostik   (Germany)

^c Institute of Translational Immunology   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Carcinoembryonic antigen; Circulating tumor cells; Epithelial cell adhesion molecule; Gastric cancer; Gastroesophageal adenocarcinoma; Keratin 19; Mucin 1; Survivin

Indexed keywords

ANTIGEN RELATED CELL ADHESION MOLECULE 5; CELL ADHESION MOLECULE; CISPLATIN; CYTOKERATIN 19; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; IRINOTECAN; MUCIN 1; OXALIPLATIN; SURVIVIN; TRASTUZUMAB; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; CARCINOEMBRYONIC ANTIGEN; CEACAM5 PROTEIN, HUMAN; EPCAM PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; BLOOD; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR EMBOLISM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84945454788     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000437373     Document Type: Article

References (33)

1. Steevens J, Botterweck AAM, Dirx MJM, van den Brandt PA, Schouten LJ: Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol 2010; 22: 669-678.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Warneke VS, Behrens H-M, Hartmann JT, Held H, Becker T, Schwarz NT, Röcken C: Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol 2011; 29: 2364-2371.
4. Laurén P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
5. Jürgensen C, Brand J, Nothnagel M, Arlt A, Neser F, Habeck J-O, Schreiber S, Stölzel U, Zeitz M, Hampe J: Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc 2013; 27: 1124-1129.
6. Okines AFC, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer 2010; 46: 1949-1959.
7. Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146-149.
8. Takeuchi H, Kitagawa Y: Circulating tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat Sci 2010; 17: 577-582.
9. Gao P, Jiao S-C, Bai L, Wang H, Jing F-F, Yang J-L: Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J Int Med Res 2013; 41: 923-933.
10. De Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, Kaul S, Stölzel U: Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 2012; 82: 3-10.
11. De Albuquerque A, Kubisch I, Stölzel U, Ernst D, Boese-Landgraf J, Breier G, Stamminger G, Fersis N, Kaul S: Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med 2012; 10: 222.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
13. Piessen G, Wacrenier A, Briez N, Triboulet J-P, Van Seuningen I, Mariette C: Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma. J Clin Pathol 2009; 62: 1144-1146.
14. MT variants in human carcinomas. J Clin Pathol 2014; 67: 408-414.
15. Tanaka K, Yano M, Motoori M, Kishi K, Miyashiro I, Shingai T, Gotoh K, Noura S, Takahashi H, Ohue M, Yamada T, Ohigashi H, Yamamoto T, Yamasaki T, Doki Y, Ishikawa O: CEA-antigen and SCC-antigen mRNA expression in peripheral blood predict hematogenous recurrence after resection in patients with esophageal cancer. Ann Surg Oncol 2010; 17: 2779-2786.
16. Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, Davison JM, Irvin CR, Hoppo T, Nason KS, Kelly LA, Gibson MK, Jobe BA: Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One 2013; 8: e78343.
17. De Albuquerque A, Kubisch I, Ernst D, Breier G, Stamminger G, Fersis N, Stölzel U, Boese-Landgraf J, Eichler A, Kaul S: Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab 2012; 58: 373-384.
18. Ross JS, Mulcahy M: HER2 testing in gastric/gastroesophageal junction adenocarcinomas: unique features of a familiar test. Gastrointest Cancer Res 2011; 4: 62-66.
19. Lurje G, Schiesser M, Claudius A, Schneider PM: Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol 2010; 2010: 392652.
20. Hwang I, Kang YN, Kim JY, Do YR, Song HS, Park KU: Prognostic significance of membrane-associated mucins 1 and 4 in gastric adenocarcinoma. Exp Ther Med 2012; 4: 311-316.
21. Imano M, Itoh T, Satou T, Yasuda A, Nishiki K, Kato H, Shiraishi O, Peng Y-F, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Furkawa H, Okuno K, Shiozaki H: High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Target Oncol 2013; 8: 231-235.
22. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H: Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 2007; 30: 171-179.
23. Gronnier C, Bruyère E, Lahdaoui F, Jonckheere N, Perrais M, Leteurtre E, Piessen G, Mariette C, Van Seuningen I: The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells. Biochim Biophys Acta 2014; 1843: 2432-2437.
24. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE: Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol 2014; 25: 1506-1516.
25. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O: Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012; 12: 178.
26. Danila DC, Pantel K, Fleisher M, Scher HI: Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J 2011; 17: 438-450.
27. Horm TM, Schroeder JA: MUC1 and metastatic cancer. Cell Adh Migr 2013; 7: 187-198.
28. Bertazza L, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D: Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med 2009; 7: 111.
29. Uen Y-H, Lin S-R, Wu C-H, Hsieh J-S, Lu C-Y, Yu F-J, Huang T-J, Wang J-Y: Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma. Clin Chim Acta 2006; 367: 55-61.
30. Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Lee SW, Choi JH, Park YT, Mok YJ, Kim CS, Kim JS: Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. Am J Clin Oncol 2005; 28: 24-29.
31. Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y: Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Hepatogastroenterology 2008; 55: 1131-1135.
32. Matsumura N, Zembutsu H, Yamaguchi K, Sasaki K, Tsuruma T, Nishidate T, Denno R, Hirata K: Identification of novel molecular markers for detection of gastric cancer cells in the peripheral blood circulation using genome-wide microarray analysis. Exp Ther Med 2011; 2: 705-713.
33. Tsujiura M, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E: Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2014; 20: 3265-3286.